Loading clinical trials...

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients | Clinical Trials | Clareo Health

RECRUITING

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

NCT07052604•Centre Hospitalier de Saint-Denis

View on ClinicalTrials.gov

Summary

This study looks at how different antibiotic treatments affect patients in intensive care who have pneumonia caused by the bacteria Stenotrophomonas maltophilia. It compares using one antibiotic versus two antibiotics, and treatment lengths of 7 days versus 14 days, to see which approach helps patients survive better. The study also examines how resistant the bacteria are to antibiotics and how often the pneumonia comes back.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult patients (age ≥ 18 years)
•Hospitalized in Medical Intensive Care Unit between January 1, 2018, and December 31, 2023
•Intubated and mechanically ventilated
•Diagnosed with ventilator-associated pneumonia caused by Stenotrophomonas maltophilia

Exclusion Criteria

•Patients under 18 years old
•Patients who refuse the use of their data for research purposes

Locations (1)

Centre Hospitalier de Saint-Denis

Saint-Denis, France, France

Key Dates

Start Date

December 15, 2023

Primary Completion Date

September 15, 2025

Completion Date

September 15, 2025

Last Updated

July 4, 2025

Enrollment

300

ESTIMATED participants

Conditions

Pneumonia, Ventilator-AssociatedStenotrophomonas MaltophiliaIntensive Care UnitsAnti-Bacterial AgentsDrug Resistance, Bacterial

Virtual Reality-Enhanced Parent Education in Neonatal Intensive Care

NCT07410858

Neonatal Intensive Care UnitsPremature Infant+3 more

View study

RECRUITING

Biomarkers for Ventilator-associated Pneumonia

NCT05117125

Pneumonia, Ventilator-Associated

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients

Inclusion Criteria

Exclusion Criteria

Virtual Reality-Enhanced Parent Education in Neonatal Intensive Care

Biomarkers for Ventilator-associated Pneumonia

Cardiac Output Measurement in Pediatric Intensive Care Unit by Metabolic Monitor (Fick Method) (PEDIA-FICK-ICU)

Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Immunocompromised Patients With Hospital-acquired Pneumonia Requiring Mechanical Ventilation

Factor Associated With Mortality in the ICU

Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections